We read with great interest the excellent meta-analysis by Marret et al. 1 and the accompanying editorial by Professor Kehlet 2 on the effects of combined opioid and nonsteroidal antiinflammatory drugs (NSAIDs) use to relieve postsurgical pain. Marret et al. conclude that NSAIDs (cyclooxygenase 2 [COX-2] selective and nonselective), in the aggregate, provide approximately 30% reduction in morphine consumption, with associated reductions in postoperative nausea and vomiting and sedation, but not pruritus, urinary retention, and respiratory depression. Although the efficacy data support the use of multimodal analgesia involving opioids and COX-2 selective NSAIDs, we believe the safety data on the short-term perioperative use of COX-2 selective inhibitors are less than clear for the following reasons.
Postsurgical Safety of Opioid-sparing Cyclooxygenase-2 Inhibitors
To the Editor:-We read with great interest the excellent meta-analysis by Marret et al. 1 and the accompanying editorial by Professor Kehlet 2 on the effects of combined opioid and nonsteroidal antiinflammatory drugs (NSAIDs) use to relieve postsurgical pain. Marret et al. conclude that NSAIDs (cyclooxygenase 2 [COX-2] selective and nonselective), in the aggregate, provide approximately 30% reduction in morphine consumption, with associated reductions in postoperative nausea and vomiting and sedation, but not pruritus, urinary retention, and respiratory depression. Although the efficacy data support the use of multimodal analgesia involving opioids and COX-2 selective NSAIDs, we believe the safety data on the short-term perioperative use of COX-2 selective inhibitors are less than clear for the following reasons.
First, the US New Drug Application for rofecoxib was based almost exclusively on studies in patients with chronic pain. Studies to directly support the postsurgical pain indication consisted of 741 patients, of whom 85% received one dose for dental pain and 15% received five doses for orthopedic pain.* Marret et al. note that the cardiovascular risk of rofecoxib was associated with "long-term use." However, in the absence of robust studies in high-risk surgical patients and based on data on parecoxib, one cannot preclude similar safety risks with short-term postsurgical use of rofecoxib.
Second, although parecoxib (the injectable prodrug of the now withdrawn valdecoxib) is an effective analgesic, there remain serious unanswered questions about the safety of short-term use in the postsurgical setting. An important early adverse postsurgical safety signal came from a coronary artery bypass graft study included in the original US New Drug Application. † In the parecoxib and valdecoxib group, 19 .0% had serious adverse events, versus 9.9% in the placebo group. Citing deficiencies in the data, including a numerically higher incidence of myocardial infarctions (1.9% vs. 0.7%) and cerebrovascular events (2.6% vs. 0.7%) and deaths (4 vs. 0), parecoxib received a nonapprovable letter from the Food and Drug Administration in 2001. The Food and Drug Administration concluded that "the adverse event profile of parecoxib was generally worse than that of placebo in this trial. Although not statistically significantly different, the number of deaths, myocardial infarctions, cerebrovascular accidents, pulmonary embolisms, along with renal and pulmonary complications were also numerically more frequent for parecoxib during this IV dosing period than placebo. In fact, during the entire study period, the incidence of these clinically relevant adverse events associated with parecoxib/valdecoxib was statistically significantly different than placebo. Similarly, during the entire study period, more patients in the parecoxib/ valdecoxib versus the placebo group withdrew from the study due to an adverse event." † Third, follow-up studies conducted with parecoxib have raised additional safety issues. In one trial, 3 cardiovascular events (including myocardial infarction, cardiac arrest, stroke, and pulmonary embolism) occurred significantly more frequently in the parecoxib and valdecoxib group than with placebo (2.0% vs. 0.5%; P ϭ 0.03). In another trial, 4 there were significantly more sternal wound infections with parecoxib than with placebo (3.2% vs. 0%; P ϭ 0.03).
Fourth, 3 yr ago, the European Medicines Evaluation Agency issued a public statement on parecoxib regarding the risk of serious hypersensitivity and skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and exfoliative dermatitis, as well as anaphylaxis and angioedema. 5 The European Medicines Evaluation Agency has since contraindicated the use of parecoxib in patients with ischemic heart disease and stroke. Excluding individuals with silent ischemia, this translates to approximately 20 million at-risk patients in the United States. Immediately before its withdrawal in the United States, the Food and Drug Administration required a similarly worded box warning for valdecoxib. Notably, the warning indicated (1) a higher risk of serious skin reactions within the first 2 weeks, (2) a greater propensity for such reactions with valdecoxib than other COX-2 inhibitors, and (3) a recommendation to discontinue valdecoxib at the first appearance of skin rash. Since self-limiting pruritus and hypersensitivity are common in the postsurgical setting, causality assessment in patients with early signs of serious and unrelated skin reactions may prove difficult.
Fifth, there are indications that the increased COX-2 levels observed under pathologic conditions in endothelial cells and atherosclerotic lesions provides atheroprotection and modulates vascular remodeling through its principal metabolite, prostacyclin. 6 In addition, in patients with acute pain, there is considerable spinal up-regulation of COX-1, which may provide a further rationale for the use of drugs that inhibit both isoforms of COX in acute pain.
Finally, survey data continue to support the view that postsurgical pain is undertreated. Although the efficacy of COX-2 selective NSAIDs such as parecoxib is comparable to nonselective NSAIDs, further safety data are required to support their short-term use in the perioperative setting.
In Reply:-We thank Drs. Babul, Sloan, and Lipman for their interest in our meta-analysis, 1 which was primarily performed to study the effects of cyclooxygenase-selective and -nonselective inhibitors on morphine side effects. We agree with them (as we discussed in the article) that some concerns remain about the safety of short-term perioperative prescription of coxibs and that coxibs cannot be administrated to all surgical patients, especially patients with coronary artery disease or at risk of cerebral infarction. Two studies have indeed clearly demonstrated that the use of parecoxib and valdecoxib was associated with an increased risk of arterial thrombotic adverse events in patients scheduled to undergo coronary artery bypass surgery. 2, 3 However, some evidence also suggests that short-term perioperative use of coxibs may offer benefits in comparison with nonsteroidal antiinflammatory drugs. For example, tonsillectomy is one of the most frequently performed ambulatory surgical procedures in children, and nonselective inhibition of cyclooxygenase by nonsteroidal antiinflammatory drugs increases significantly the rate of reoperation 4,5 but also decreases nausea and vomiting. 5 In that setting, celecoxib, has been demonstrated to relieve posttonsillectomy pain and to decrease bleeding risk in comparison with nonsteroidal antiinflammatory drugs. 6 Moreover, the risk of adverse cardiovascular events is extremely low in this population of young patients, as it is in patients devoid of arterial thrombotic pathology scheduled to undergo noncardiac surgery. Therefore, short-term perioperative use of coxibs could have a favorable risk-benefit ratio compared with nonsteroidal antiinflammatory drugs in patients without risk factors for arterial thrombotic events submitted to hemorrhagic surgical procedures. 
Facilitating Endotracheal Tube Advancement during Fiberscope-assisted Intubation: Giving Due Credit
To the Editor:-Johnson et al.'s 1 pictorial documentation of the structures that obstruct the passage of an endotracheal tube during fiberoptic intubation is brilliant and once again proves the usefulness of a 90°counterclockwise rotation of the endotracheal tube to facilitate advancement. 2 Unfortunately, they have, like some authors before them, failed to acknowledge the contribution of Dr. Cossham, who first described this technique to facilitate the passage of an endotracheal tube over a gum elastic bougie. 3 When passage of an endotracheal tube over a fiberscope is difficult, most clinicians had, hoping to bypass the obstruction, retried while or after twisting the tube left or right-a somewhat haphazard maneuver also mentioned by Ovassapian et al. 4 It was Dr. Cossham, however, who actually clearly illustrated the technique. Whether over a gum elastic bougie or over a flexible bronchoscope, his technique is elegant and proven, 5 and the principles are the same. It is such a useful "trick" that we believe that the first attempt to advance an endotracheal tube over a flexible bronchoscope should always be made with it already turned counterclockwise by 90°. 6 Our experience is that the success rate exceeds 90% with only one attempt, thus saving time and reducing the risk of upper airway trauma and unpleasantness for the patient.
Fiberoptic Intubation
To the Editor:-We read with interest the recent report by Johnson et al. 1 about problems encountered during fiberoptic intubations. This study validated our findings from 1989, where we showed that difficulty passing an endotracheal tube over a bronchoscope is most commonly due to contact with the right arytenoid. 2 Similar to Johnson et al., we demonstrated that 90°rotation of the tube should be the first maneuver to advance the tube over the arytenoid. 2, 3 We have formally taught this technique to our residents during the past 10 yr. 4 Of further interest, we have reported that contact with the right aryepiglottic fold is also the most common cause for difficulty in advancing an endotracheal tube using a Bullard laryngoscope. 5 
Difficulties in Advancing an Endotracheal Tube over a Fiberoptic Bronchoscope
To the Editor:-I read with interest the report of Johnson et al., 1 assessing the reasons for difficulties in advancing an endotracheal tube over a fiberoptic bronchoscope. They state that their study is the first to provide pictorial evidence of the laryngeal structures that obstruct passage of the endotracheal tube during fiberoptic intubation. I point out that this statement is not correct: I had already shown pictorial evidence of this in 2002, using a method similar to theirs. 2 They stated that the right arytenoid and the interarytenoid soft tissues were the sites of resistance to advancement of the endotracheal tube during awake fiberoptic orotracheal intubation. 1 This supports my statement in a review article on this topic that the main reasons for difficulty in advancing a tube over a fiberscope is that the tube tends to move posteriorly to the glottis. 3 Another possible reason for the difficulty, that they did not observe, but I did, was that the endotracheal tube entered the esophageal inlet. 2 There have been reports of esophageal intubation despite correct insertion of a fiberscope into the trachea. 3, 4 I have found that a curved tube was often advanced directly into the esophageal inlet, without impacting on the arytenoid cartilage. 2 In such a case, resistance was felt, not because the tube was impacting on the arytenoids, but because it was pushing the midsegment of the fiberscope into the esophagus. These findings can explain why rotation of the tube does not always enable the tube into the larynx and why withdrawing the tube for a few centimeters (to remove the tube tip out of the esophagus) before rotating and advancing the tube would often facilitate tracheal intubation. I also have shown that cricoid pressure reduces the difficulty in advancing a tube over a fiberscope, by compressing the esophageal inlet. 2 Johnson et al. have shown a variable finding that, when a fiberscope is located in contact with the arytenoids, it is more likely to be difficult to advance a tube into the trachea. They also stated that other factors (e.g., awake vs. anesthetized) may also have played a role. I suggest that the difference between their and my studies in the incidence of esophageal intubation may be caused by a difference in the head and neck position. Most patients in the study of Johnson et al. 1 were neurosurgical cervical spine patients, and optimal positioning of the head and neck were limited, whereas in my study, 2 the head was placed on a pillow and mildly extended. The esophageal inlet is more likely to be open when the head is extended (imagine that, when one drinks, one would place the head and neck to a similar position to this, to open the esophageal inlet). Therefore, the incidence of an endotracheal tube migrating into the esophageal inlet, in theory, is reduced by placing the head and neck into the neutral position.
Fiberoptic intubation is an established useful method in patients with difficult airways. Nevertheless, as Johnson et al. 1 pointed out, repetitive attempts at advancing a fiberscope into the trachea and advancing a tube over the scope increase the risk of injury to the larynx and surrounding tissues, leading to bleeding from, or edema of, the tissues. Because the causes of difficulty in tracheal intubation over a fiberscope and the inefficacy of each solution method have not been elucidated fully, we must continue to study to make fiberoptic intubation safer. 
UNDO Your Troubles with the Tube: How to Improve Your Success with Endotracheal Tube Passage during Fiberoptic Intubation
To the Editor:-The article by Johnsen et al. 1 once again highlights a problem commonly faced by practitioners using a fiberoptic scope to intubate the trachea, i.e., resistance to passage of the endotracheal tube. As they discuss, this is usually attributed to the endotracheal tube being caught on structures of the supraglottic airway. [2] [3] [4] [5] [6] Johnson et al. correctly report that when oral fiberoptic intubation is attempted, the most common cause of obstruction to endotracheal tube placement is the right arytenoid cartilage. The article that best describes the anatomical reasons for endotracheal tube obstruction is based on observation of obstruction to endotracheal tube placement in an intubating mannequin. 3 Unfortunately, Johnson et al. neglect to credit this investigation, which found the same cause of obstruction, albeit not in human subjects, as they now report. In addition, as we reported in a letter to the editor of this journal, we have had years of experience with a high degree of successful oral endotracheal tube passage over the fiberscope in children and adults using the method of beginning with the bevel in the down position or facing posteriorly. 7 For example, in one of our recent publications examining the best method to teach fiberoptic intubation to residents, we found a high degree of successful initial endotracheal tube passage over the fiberscope. By paying strict attention to bevel orientation, we had only 3 failures of 300 intubation attempts that were secondary to inability to pass the endotracheal tube. 8 Overall, intubation was successful in 292 of 300 attempts; the 5 additional failures were secondary to being unable to correctly place the fiberscope. 8 This is a far higher success rate than the 50% obstruction Johnson et al. report when the bevel orientation is not down or posterior. It should also be noted that anatomical obstruction for nasal intubation differs. 3 In this case, obstruction is usually secondary to the epiglottis, and, as we have advocated and continue to teach, when nasal intubation is performed, the bevel orientation should be up or facing anteriorly to assure the highest rate of successful endotracheal tube passage. An easy mnemonic to assist in remembering the endotracheal tube orientation is "UNDO your troubles with the tube"-i.e., bevel Up for Nasal fiberoptic intubation and bevel Down for Oral fiberoptic intubation. 
Markedly Displaced Arytenoid Cartilage during Fiberoptic Orotracheal Intubation
To the Editor:-We read with great interest the article by Johnson et al. 1 in which the right arytenoid inhibited the advancement of the endotracheal tube (ETT) into the trachea during awake fiberoptic orotracheal intubation. We have been observing the process of oral fiberop-tic intubation during general anesthesia with the use of the similar double-fiberscope technique and reported a case in which the right arytenoid cartilage prevented the ETT passage and the tube rotation solved the problem. 2 This problem often occurs not only during awake fiberoptic intubation but during general anesthesia. Moreover, we experienced a case in which the ETT threaded over the fiberscope displaced the right arytenoid markedly despite gentle tube advancement ( fig. 1 ). In this case, the operator could not feel the resistance until the ETT displaced the arytenoid markedly because the laryngeal tissues were soft, floppy, and relaxed. Therefore, we agree with the authors that this problem can lead to serious laryngeal injury and should be solved.
To avoid this problem, the authors recommend that the fiberscope should be placed in the center of the larynx before tube advancement. However, in usual intubation situations, the fiberscope itself cannot be seen, and the position relative to the larynx cannot be identified. The fiberscope position may be changed during tube advancement. When the ETT cannot be passed into the trachea, the operator cannot identify whether the fiberscope is placed in the center. Therefore, it would be difficult to control the fiberscope position in the center of the larynx. For successful intubation, we should carefully consider other factors (i.e., the size and type [design] of the ETT, 3,4 the fiberscope size, 5 and the sleeve for the fiberscope 6,7 ) before the intubation procedure. In any case, the ETT should be rotated at the first tube advancement.
Finally, regarding the study method, when the nasally placed second fiberscope for observation of the intubation procedure is positioned in the center against the larynx, it may be difficult for the operator to introduce the fiberscope for intubation in the center. If the fiberoptic view for observation is obtained from the left or right side, the intubating fiberscope position looks near another side. It seems to be difficult to identify the "true" fiberscope position.
In Reply:-I am delighted with the interest our recent article 1 sparked, and I thank the Editor-in-Chief for this opportunity to respond. I find common themes in all six letters. First, the subject of fiberoptic intubation is interesting and important. Second, more research is needed in this field. Third, several of the authors reported in one way or another in letters to the editor or clinical reports that endotracheal tubes stop at the arytenoid during fiberoptic intubation. Fourth, clinical observations in correspondences or clinical reports are good sources of ideas for rigorous scientific studies. Finally, for the record, Dana Johnson is not an M.D. yet. She is an outstanding medical student at the Carver College of Medicine at The University of Iowa (Iowa City, Iowa). I thank all of the authors for their insightful remarks and their interest in our article.
I agree with Drs. Ho and Karmakar that Cossham, in a letter to the editor in 1985, described the technique of inserting an endotracheal tube turned 90°counterclockwise over a gum elastic bougie in anesthetized patients. 2 I did refer to Cossham's letter in a previous article that described three cases of trauma to the airway by fiberoptic intubation. 3 This was not the focus of the study and I certainly do not claim that I introduced this technique. The focus was to identify the structures that inhibit endotracheal tube advancement over a fiberoptic bronchoscope. I believe this goal was achieved. I apologize for not referring again to Dr. Cossham's contribution.
Dr. Benumof is right, and I am right too. The corniculate cartilage is different from the arytenoid cartilage, although they are intimately related. According to Gray's Anatomy, the arytenoid cartilage is described in this fashion: "The apex of each cartilage is pointed, curved backward and medialward, and surmounted by a small conical, cartilaginous nodule, the corniculate cartilage" and also in this fashion: "The corniculate cartilages (cartilagines corniculatae cartilages of Santorini) are two small conical nodules consisting of yellow elastic cartilage, which articulate with the summits of the arytenoid cartilages and serve to prolong them backward and medialward." Also according to Gray's Anatomy, another small cartilage, the cuneiform cartilage, also sits on the apex of the arytenoid cartilage. 4 Both corniculate and cuneiform cartilages may or may not be present in humans. The arytenoid is the one that dislocates after traumatic intubations, not the corniculate or the cuneiform. In the medical community, the term arytenoid is the one in common use and refers to the arytenoid complex, which encompasses all three structures. When the progress of the endotracheal tube is inhibited by the arytenoid cartilage, the tip of the tube may be stopped at the top of the arytenoids where the corniculate and the cuneiform cartilages are located, or it may reach all the way to the posterolateral aspect of the arytenoid cartilage at the cricoarytenoid junction, as is well illustrated in figure 1A of our article. 1 I am aware of the remark of Schwartz et al. 5 in a letter to the editor in 1989, and I apologize for not referring to it.
Dr. Asai, I read your article, Asai et al., 6 as well as your many other writings on fiberoptic intubation. In your article, you used two fiberoptic bronchoscopes simultaneously, as I did in my research, 1 one inserted orally and the other inserted through the nose. Having said that, I stand behind my statement that "our study is the first to provide pictorial evidence of the laryngeal structures that obstruct the passage of the [endotracheal tube] during fiberoptic intubation." In your article, you report that in 2 of 10 patients, the arytenoid cartilage stopped the advancement of the endotracheal tube. This is a perfectly valid clinical observation that was not supported by statistical analysis. I do agree that during the process of threading the tube over a bronchoscope, it is possible for the tube to enter the esophagus, although I did not make this observation in clinical practice or research.
In the article, I studied only oral fiberoptic intubation. I did not study nasal fiberoptic intubation. I agree with Drs. Wheeler and Dsida that the dynamics of threading the endotracheal tube are different in both types of intubations. With regard to oral fiberoptic intubation, the dynamics and the motility of the larynx and threading the endotracheal tube are widely variable between awake and anesthetized patients, let alone adding a plastic static human mannequin model into the comparison. Therefore, comparisons between a success rate of 298 in 300 in your study in threading the endotracheal tube in anesthetized patients 7 and my success rate (50%) in awake patients should not be made, because they are two different clinical situations.
In Aoyama et al., 8 you made a valid clinical observation of the endotracheal tube stopping at the arytenoid cartilage. I did not encounter significant difficulties in determining the position of the fiberscope in relation to the arytenoids because, as shown in the pictures, the nasal fiberscope came very close to the oral fiberscope and the laryngeal structures. As you and Dr. Wheeler mention in your letters, there are many methods to facilitate successful threading of the endotracheal tube over the fiberscope. To the Editor:-I read with interest the article of Dixon et al. 1 The results show in the class III obese patients that preoxygenation in the 25°head-up position achieves 23% higher oxygen tensions, allowing a clinical increase in the desaturation safety period. The report postulated that preoxygenation in the head-up position may be advantageous in many other clinical circumstances in which respiratory function may be impaired in the supine position, e.g., advanced pregnancy, ascites, bowel obstruction. Baraka et al. 2 (1992) reported about "Preoxygenation of Pregnant and Nonpregnant Women in the Head-up versus Supine Position." The results showed that after 3 min of preoxygenation, desaturation to 95% during subsequent apnea, as monitored by pulse oximetry, was more rapid in pregnant than in nonpregnant patients. Also, changing from the supine to the 45°head-up position prolonged the desaturation time in the nonpregnant women but had no significant effect in the pregnant women (table 1). These results were unanticipated because a change from the supine to the sitting position has been shown to increase the functional residual capacity in both pregnant 3 and nonpregnant patients. 4 
Mechanism of Benefit of Head-up Preoxygenation in Obese Patients
To the Editor:-I read with interest the study report in the June 2005 issue of ANESTHESIOLOGY by Dixon et al. 1 regarding the benefits of head-up preoxygenation in obese patients. Although I do not dispute the basic findings of the study or the benefit of head-up position in obese patients, I question the conclusions drawn in the abstract and discussion.
Although there was a strong correlation between oxygen tension and time to desaturation, it cannot be concluded that the higher arterial oxygen tension (PaO 2 ) itself was protective. The oxygen content of blood in the form of dissolved oxygen under nonhyperbaric pressure conditions is minimal. At the preinduction PaO 2 achieved after 3 min of preoxygenation in both supine and head-up subjects, hemoglobin would be expected to be 100% saturated, providing maximal blood oxygen content in both study groups. The additional time to desaturation afforded by the small increase in dissolved oxygen reserve in the head-up group is unlikely to have been significant. More likely, the benefit of head-up positioning in delaying desaturation (as well as increasing PaO 2 ) is a result of factors of pulmonary mechanics mentioned in the study background as they relate to oxygen reserve.
Also for this reason, changing the patient's position from head-up to supine at induction as suggested possible to ease intubation may partially or completely negate the benefits of the head-up preoxygenation despite the increased preinduction PaO 2 . This repositioning maneuver might be useful in a follow-up study to test this hypothesis. In Reply:-We thank Drs. Wax and Baraka for their interest in our article on the benefits of the head-up position for preoxygenation in class III obese patients. 1 They draw attention to two aspects of our article.
It is interesting that Dr. Baraka et al. 2 found, in a small study of similar design, no benefit in desaturation safety with preoxygenation in the 45°head-up position in pregnant women at term. Perhaps as speculated, the effect of the gravid uterus on the movement of the diaphragm has a negative impact on lung mechanics. Although the gravid uterus does decrease functional residual capacity, the mechanism and distribution of mass are considerably different to those seen in obesity, and therefore, the favorable effects we found with posture change may not be applicable. Our comments were speculative only, indicating that the head-up position may achieve a prolongation of the desaturation safety period. The gravid uterus may have a varying impact on lung mechanics depending on the posture: supine, 25°, 45°, and sitting up. This is an area for further research because severe obesity and the advanced gravid state are associated with increased difficulty in airway management and higher metabolic rates increasing the risk of hypoxia during anesthetic induction. Oxygen tensions taken in various positions may assist in optimizing preoxygenation, and further investigation into the role of position in preoxygenation should continue in several high-risk groups.
Dr. Wax correctly points out that the dissolved oxygen in blood under atmospheric conditions is trivial and unlikely by itself to alter the desaturation safety period. We agree and indicate within the discussion that the aim is to optimize lung oxygen content by achieving a posture that provides optimal respiratory mechanics, lung volumes, functional residual capacity, and arterial oxygen tension during preoxygenation. We found a strong correlation between the oxygen tension achieved and the desaturation safety period suggesting that end preoxygenation oxygen tension is an indicator of improved pulmonary oxygen reserves. We speculate that the extended desaturation safety period in head-up subjects is due to continued oxygenation of blood from increased pulmonary reserves and not directly due to the higher initial oxygen tension. In addition, we caution that after head-up preoxygenation, a change to the supine position for intubation may reduce these favorable conditions and shorten the desaturation safety period. 
Sildenafil for Pulmonary Hypertension in Pregnancy?
To the Editor:-We read with interest the comprehensive series presented by Bonnin et al. 1 Their report of the treatment of severe pulmonary hypertension (PHTN) during pregnancy in their institution from 1992 to 2002 is a timely reminder of the high maternal and fetal mortality from this condition. We would like to draw the readers' attention to the emerging role of phosphodiesterase inhibitors (PDEs), such as sildenafil, in the treatment of PHTN. Clinical trials have demonstrated that oral sildenafil is effective in the treatment of both acute and chronic PHTN 2-4 of a variety of etiologies. 5, 6 In addition, several recent reports exist of its successful use in pregnant patients with this devastating disease process. 7, 8 Phosphodiesterase inhibition has been demonstrated to treat PHTN by reducing cyclic guanosine monophosphate breakdown, making pulmonary vascular smooth muscle more sensitive to endogenous and administered nitric oxide. 9 This reduces ventilation perfusion mismatch and hypoxia. 3, 10 Of the PDE5 inhibitors studied, sildenafil has the greatest selectivity for the pulmonary circulation and arterial oxygenation. 11 The use of PDE inhibitors seems safe in both ischemic heart disease 12 and heart failure. 13 The effect of PDEs on pulmonary vasculature and pulmonary artery pressure has been studied in comparison to and in combination with inhaled iloprost and inhaled nitric oxide, 14 -16 and it augments their vasodilatory effects. 17, 18 In fact, sildenafil is at least as effective as inhaled nitric oxide in relaxing the pulmonary vasculature and may have fewer side effects. 19 Coadministration of sildenafil with nitric oxide also leads to less rebound PHTN, a major problem with nitric oxide administration, caused by downregulation of nitric oxide synthetase. 15 Sildenafil has other potentially beneficial effects in this context. It causes uterine artery vasodilation and has been shown to improve uterine muscle wall thickness in in vitro fertilization patients with previous poor endometrial response. 20 In addition, sildenafil and nitric oxide are being used successfully to treat preterm and term neonatal and childhood PHTN. 21, 22 The therapeutic potential of sildenafil in the treatment of PHTN during pregnancy awaits definitive demonstration in the form of a clinical trial. However, its proven effectiveness and safety in other forms of pulmonary hypertension, coupled with ease of oral administration and its apparent lack of teratogenicity, mean that it is a highly promising therapy for severe pulmonary hypertension in pregnant patients. , M.B., B.Ch., B.A.O.,* John G. Laffey, M In Reply:-We thank Drs. Lynch and Laffey for their interest in our series of 15 cases of severe pulmonary arterial hypertension (PAH) during pregnancy and their useful comment on therapeutic options. 1 Our series gathered patients from 1992 to 2002. During this period, therapeutic options have expanded markedly and patient management has become more active. Nonetheless, even when considering our most recent cases only, pregnancy must be still discouraged undoubtedly. Therefore, therapeutic abortion is the first-line treatment we offer to patients who are pregnant already. In our experience, however, some patients decline this option. For these patients who are willing to continue with their pregnancy, it is particularly important to make sure that an updated optimal treatment is actually implemented. Although there is no curative treatment for idiopathic PAH, several drugs are now available to target the main dysfunctional pathways of the disease.
Tadhg D. Lynch
These drugs included namely (1) prostaglandin I 2 (prostacyclin), (2) endothelin-1 receptor antagonists, and (3) type 5 phosphodiesterase inhibitors. According to our group 2 and to European 3 and American 4 guidelines, intravenous prostacyclin (epoprostenol) is the treatment of choice for patients with PAH in functional class IV. For patients with PAH in functional class III, endothelin-1 receptor antagonists or prostacyclin analogs (inhaled iloprost or subcutaneous treprostinil) may be used as an alternative. Guidelines do not provide specific recommendations in pregnant patients with regard to drug choice, except that the endothelin-1 receptor antagonist bosentan should be contraindicated. 2, 4 This is because animal data indicate that bosentan could provide potential major birth defects. 5, 6 Sildenafil is the first type 5 phosphodiesterase inhibitor approved for clinical use in the United States in patients with PAH, and it is currently in registration process in Europe (20 mg three times a day). As pointed out by Drs. Lynch and Laffey, it has several advantages over inhaled nitric oxide, and it is also particularly appealing for long-term treatment because of its oral administration, in contrast to other drugs. However, despite a few promising reports, more information is needed in pregnant patients with functional class III or IV PAH before it could be considered as a true alternative option to the above-mentioned guidelines. Meanwhile, we believe that prostacyclin therapy is a more validated approach. 7 Whatever the drug or combination of drugs chosen, it is important to report back both the positive and negative outcomes observed, because the experience remains (we hope) particularly scarce in this subpopulation of pregnant patients.
Effectiveness of Isoflurane in Inducing Delayed Preconditioning against Myocardial Infarction In Vivo
To the Editor:-We read with great interest the article by Chiari et al. 1 regarding a potential role of endothelial nitric oxide synthase in isoflurane-induced delayed preconditioning in rabbit myocardium. The authors are to be congratulated for performing an important study about the remote effects of isoflurane in attenuating myocardial infarct after acute coronary occlusion and reperfusion. In particular, they addressed the potential role of endothelial nitric oxide synthase and subsequently of nitric oxide in isoflurane-induced myocardial protection. Nitric oxide donors have been shown to mimic the protective effects of delayed ischemic preconditioning in rabbits. 2 The protective effect of nitric oxide donor was completely abrogated when this agent was given in conjunction with the peroxynitrite (ONOO-) and hydroxyl radical (.OH) scavenger mercaptopropionyl glycine, 2 suggesting nitric oxide induced late preconditioning involved the generation of reactive oxygen species. This is similar in nature to isoflurane in that isoflurane preconditioning requires the generation of reactive oxygen species as a trigger. 3 Furthermore, transient systemic ischemic preconditioning enhanced early functional recovery of reperfused hearts in the rabbits, accompanied by an increase in plasma nitric oxide concentration as well as increases in plasma superoxide dismutase activi-ty. 4 This latter observation seems to suggest nitric oxide as a potential mediator of ischemic preconditioning in rabbits. This is supportive of the study of Chiari et al. 1 showing that endogenous nitric oxide may function as a mediator of isoflurane-induced delayed preconditioning.
It should be noted, however, that in all of the studies 1-4 mentioned above, the duration of coronary occlusion was limited to 30 min. A study conducted by Kehl et al. 5 (from the same research group as Chiari et al. 1 ) clearly demonstrated that isoflurane did not produce a delayed preconditioning against myocardial infarction in vivo in dogs when the duration of coronary occlusion was extended to 60 min. Although the animal species used are different in the two studies, 1,5 the duration of coronary occlusion could have played a determinant role regarding the effectiveness of isoflurane in inducing delayed preconditioning against myocardial infarct. It is unexpected that Chiari et al. 1 did not comment on this potential limitation of isoflurane preconditioning effects. Study has shown that in ischemic-reperfused isolated guinea pig hearts, the therapeutic time frame for anesthetic preconditioning against postischemic contractile dysfunction and infarction is approximately 25-40 min. 6 The protection is maximal when ischemic duration is between 30 and 35 min. This suggests that anesthetic preconditioning may be useful therapy only if the typical duration of ischemia during coronary artery bypass falls within this range. Therefore, we have good reason to postulate that isoflurane-induced delayed preconditioning, if any, is confined to a specific time frame.
As commented by Chiari et al. in the Discussion, aging modulates (reduces the efficiency of) anesthetic preconditioning. One possible explanation for this phenomenon is that antioxidant capacity is reduced with aging. That is, aging is associated with increased formation of reactive oxygen species. Therefore, theoretically, further enhancement of oxygen free radical production by volatile anesthetics may even prove to be detrimental to an aged population. The oxygen free radical-induced lipid peroxidation end product 15-F 2t -isoprostane per se has been shown to be an independent risk marker of cardiac complications and can exacerbate myocardial ischemia-reperfusion injury. 7 In contrast to volatile anesthetics, the intravenous anesthetic propofol has antioxidant property and has been shown experimentally to better protect hearts of aging animals than hearts of younger animals against postischemic myocardial injury. 8 Large prospective clinical trials comparing volatile anesthetic preconditioning and intravenous "anesthetic treatment" or trials comparing a combination of the two are merited, in particular, in the aged population or in those patients with an expected duration of ischemia during coronary artery bypass longer than 40 min. In Reply:-We thank Xia et al. for their gracious comments about our recent work characterizing the role of endothelial nitric oxide synthase in delayed preconditioning against myocardial infarction produced by isoflurane. 1 The authors mention that isoflurane-induced preconditioning requires the generation of reactive oxygen species. In fact, we have previously demonstrated that isoflurane produces small quantities of reactive oxygen species independent of ischemia and reperfusion as detected using dihydroethidium staining and confocal laser microscopy. 2 These data provided direct evidence that exposure to isoflurane produces a small burst of reactive oxygen species via opening of mitochondrial adenosine triphosphate-sensitive potassium channels that triggers preconditioning. 3 Xia et al. suggest that the duration of coronary artery occlusion may contribute to the relative efficacy of volatile anesthetics during acute or delayed preconditioning. Previous data indicated that isoflurane did not produce delayed preconditioning in dogs exposed to a 60-min left anterior descending coronary artery occlusion, 4 in contrast to the findings in rabbits when a 30-min coronary occlusion was used. 1 Although these results may have been related to the duration of coronary occlusion, it is more likely the findings were related to differences in systemic hemodynamics and coronary collateral blood flow between species. Coronary artery occlusions of 30 or 60 min in duration typically produce myocardial infarct sizes of approximately 40 and 33% in rabbits and dogs, respectively. Heart rates in barbiturateanesthetized rabbits and dogs are approximately 240 and 130 beats/ min, respectively. As a result, myocardial oxygen consumption before and during coronary occlusion is substantially higher in rabbits as compared with dogs. In addition to this more pronounced ischemic burden, rabbits have little if any coronary collateral blood flow. 5 In contrast, the canine model of ischemia and reperfusion used in our previous investigation 4 is complicated by variable degrees of coronary collateral perfusion, which must be considered when interpreting the results. We believe that it would also be premature to extrapolate our findings in barbiturate-anesthetized, acutely instrumented rabbits 1 to patients with coronary artery disease undergoing cardiac surgery using cardiopulmonary bypass, as suggested by Xia et al. In contrast to the arguments of Xia et al., there is little experimental evidence supporting the hypothesis that propofol produces substantial cardioprotective effects against ischemia-reperfusion injury in vivo. However, a large body of experimental evidence supports the contention that volatile anesthetics exert important protective effects against reversible and irreversible ischemic injury. 6 To date, several clinical trials have provided preliminary data to corroborate these experimental findings. In particular, De Hert et al. 7 demonstrated that sevoflurane but not propofol preserved myocardial function and attenuated increases in troponin I release in patients undergoing coronary artery bypass graft surgery. These data suggested that sevoflurane but not propofol produces myocardial protection in humans at risk for ischemic injury. 7 Further large-scale, multicenter clinical trials should be performed to define the utility of volatile anesthetics as cardioprotective agents in humans.
In Reply:-We appreciate the interest and comments of Drs. Mahajan, Gupta, and Sharma regarding our Review Article about postoperative pruritus. 1 In our Review Article, we summarized coexisting conditions that contribute to the choice of anesthesia and treatment of postoperative pruritus. Two major purposes for our article were (1) to summarize up-to-date knowledge about prevention and treatment of itching after surgery and (2) to illustrate basic principles for diagnosis and treatment for postoperative itching for practicing anesthesiologists. We appreciate the suggestions of Dr. Mahajan et al. 2 that anesthesiologists should be vigilant about the Koebner phenomenon in patients with certain skin diseases and avoid the use of medications that would lead to pruritus.
In a variety of skin diseases, trauma to the skin may result in the isomorphic Koebner phenomenon. [3] [4] [5] We would like to emphasize that exacerbation of coexisting skin disease is not a sequela to pruritus. To the best of our knowledge, there is no study that linked mechanisms of pruritus with the Koebner phenomenon. Of course, if itching is left untreated, it may lead to scratching, and trauma caused by scratching (but not to itching per se) may cause the Koebner phenomenon. Our review focused on early diagnosis and treatment of pruritus not only to avoid sequelae of itching (scratching, as well as the isomorphic Koebner phenomenon in certain cutaneous diseases), but also to improve patients' satisfaction and to shorten their time in the recovery room. In addition, we emphasized the increasing need for effective preventive measures, which are often still missing.
Also, we think that in the future, anesthesiologists will have access to more specific drugs that will act only at the intended receptor. With them, anesthesiologists will be able to modulate specific sites for specific anesthetic and surgical goals instead of causing undesirable effects (such as itching). In Reply:-The interest of Dr. Sosis in our recent article 1 demonstrating the absence of a clinically significant effect of low-dose droperidol on the QT interval after a propofol induction is appreciated. As stated in my earlier editorial, 2 despite widespread clinical use in anesthesia for more than 30 yr, not a single case report describing a droperidol-induced arrhythmia has appeared in the peer-reviewed anesthesia literature despite the US Food and Drug Administration-imposed "black box" warning (excluding the questionable case report 3 mentioned by Dr. Sosis, which appeared in a Japanese journal in 2002). Even with extensive use of high-dose droperidol as part of a standard "neurolept" anesthetic technique, there have not been any reported cases of droperidol-induced dysrhythmias during anesthesia.
In considering the facts of this particular case report, 3 Dr. Sosis neglected to mention that the administered dose of droperidol was more than 10 times the standard antiemetic dosage. Second, the alleged case of droperidol-induced multifocal ventricular dysrhythmias occurred in a woman with chronic renal failure who was receiving hemodialysis. Importantly, there was no mention of her electrolyte status at the time of the acute event. Third, she was given a 10-mg intravenous bolus dose of droperidol during general inhalation anesthesia with a combination of isoflurane and nitrous oxide. This combination of inhaled and intravenous drugs would hardly be described as classic neurolept anesthesia. I stand by my earlier published statements that there has not been a single documented case of a serious cardiac arrhythmia occurring in a patient receiving an antiemetic dose (e.g., 0.625-1.25 mg) of droperidol or even a large dose of droperidol (e.g., 10 mg) as part of a true neurolept anesthetic technique. Hopefully, the decision-makers at the Food and Drug Administration will come to their senses and remove the unwarranted black box warning on this highly cost-effective antiemetic drug. values of 720, 615, 742, and 641 ms at 1, 2, 3, and 4 h after surgery, respectively. The patient's postoperative recovery was completely uneventful, and she was discharged home despite the persistently prolonged QTc interval. If this patient had received droperidol (or one of the 5-hydroxytryptamine type 3 antagonists 4 ) for antiemetic prophylaxis, this otherwise "unexplained" prolongation of the QTc interval in the postoperative period would almost certainly have been incorrectly ascribed to the antiemetic drug.
In a recent perspective on drugs and the QT interval, Liu and Juurlink 3 stated that "most of what is known about drug-induced QT-interval prolongation derives from spontaneous reporting mechanisms." Unfortunately, these anecdotal reports are not subject to peerreview, and other potential causative factors for a resultant dysrhythmia are often overlooked. Analogous to the widely used antibiotic erythromycin, droperidol has been successfully used by anesthesiologists for the treatment and prevention of postoperative nausea and vomiting in millions of patients during the past 30ϩ years. 5, 6 As a result of the FDA-imposed "black box" warning mandating additional electrocardiographic monitoring when this cost-effective antiemetic is administered, droperidol has been effectively eliminated from the anesthesiologist's armamentarium at many medical centers in this country and abroad. As pointed out by Roden 7 in his recent review article on drug-induced prolongation of the QT interval, "since rare side effects occur with many otherwise highly-effective drugs, their withdrawal from the market probably harms more patients than it helps."
In the opinion of many clinicians around the world, the FDA's recent obsession with drug-induced QT prolongation is an example of "mak-ing a mountain out of a molehill." 8 Could someone please explain the basis for the FDA's preoccupation with an apparent nonproblem of QT prolongation in the population at large? Paul F. White, Ph.D., M.D., F.A.N.Z.C.A.,* Joao Abrao, M.D., Ph.D., *University of Texas Southwestern Medical Center, Dallas, Texas. paul.white@utsouthwestern.edu supranormal tidal volume breaths. There seemed little need to have the patient manually pinch the nose to prevent nasal breathing, although this may certainly be an option in some patients.
To determine the efficiency of the MTC technique, we conducted an institutional review board-approved, minimal risk protocol in 10 healthy, nonclaustrophobic volunteers. End-expired oxygen, nitrogen, and carbon dioxide concentrations were measured with a Rascal II gas monitor (Ohmeda, Louisville, CO) via a sampling catheter attached to the L-piece of the circuit. Each volunteer pinched his own nose closed. Measurements were recorded before initiation of preoxygenation and at 30, 60, 90,120, 150, and 180 s thereafter. The study divided the volunteers into two groups and used a crossover design. Mean concentrations of circuit oxygen, nitrogen, or carbon dioxide were similar between the two arms of the study. For example, mean carbon dioxide concentrations never differed by more than 1 mmHg, denoting constant respiratory effort. Circuit nitrogen concentration (mean Ϯ SD) for MTC versus facemask breathing were 25 Ϯ 5 and 30 Ϯ 7%, respectively, at 30 s; 11 Ϯ 5 and 15 Ϯ 6% at 60 s; 3 Ϯ 2 and 6 Ϯ 5% at 120 s; and 2 Ϯ 1 and 4 Ϯ 6% at 180 s.
After preoxygenation with this technique and anesthesia induction with an intravenous drug, ventilation of the lungs can be rapidly converted to a standard mask technique immediately after the patient loses consciousness.
The advantages of the MTC technique for claustrophobic patients are that it requires no special equipment, the patient's face is not covered by a mask, and the patient is in total control of the airway (hence reducing the sense of helplessness). When a complete seal is formed around the L-connector and mouth breathing is used exclusively, the oxygen wash-in, nitrogen wash-out properties of the patient-circuit unit should be nearly identical to that attained with the more traditional mask-facilitated preoxygenation used in nonclaustrophobic patients. 
